A causal role for endothelin-1 in the vascular adaptation to skeletal muscle deconditioning in spinal cord injury. by Thijssen, D.H.J. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/53025
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
A Causal Role for Endothelin-1 in the Vascular Adaptation
to Skeletal Muscle Deconditioning in Spinal Cord injury
Dick H.J. Thijssen, Reinier Ellenkamp, Miriam Kooijman, Peter Pickkers, Gerard A. Rongen,
Maria T.E. Hopman, Paul Smits
Objective—Endothelin-1 (ET-1) contributes to the increased peripheral resistance in heart failure and hypertension.
Physical inactivity is associated with cardiovascular disease and characterized by increased vascular tone. In this study,
we assess the contribution of ET-1 to the increased vascular tone in the extremely deconditioned legs of spinal
cord-injured (SCI) individuals before and after exercise training.
Methods and Results—In 8 controls and 8 SCI individuals, bilateral thigh blood flow was measured by plethysmography
before and during the administration of an ETA/ETB-receptor blocker into the femoral artery. In SCI, this procedure was
repeated after 6 weeks of electro-stimulated training. In a subset of SCI (n4), selective ETA-receptor blockade was
performed to determine the role of the ETA-receptors. In controls, dual ET-receptor blockade increased leg blood flow
at the infused side (10%, P0.05), indicating a small contribution of ET-1 to leg vascular tone. In SCI, baseline blood
flow was lower compared with controls (P0.05). In SCI, dual ET-receptor blockade increased blood flow (41%,
P0.001). This vasodilator response was significantly larger in SCI compared with controls (P0.001). The response
to selective ETA-receptor blockade was similar to the effect of dual blockade. Electro-stimulated training normalized
baseline blood flow in SCI and reduced the response to dual ET-receptor blockade in the infused leg (29%, P0.04).
Conclusion—ET-1 mediates the increased vascular tone of extremely inactive legs of SCI individuals by increased
activation of ETA-receptors. Physical training reverses the ET-1-pathway, which normalizes basal leg vascular tone.
(Arterioscler Thromb Vasc Biol. 2007;27:325-331.)
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The endothelium plays an important role in the regulationof vascular tone via the release of vasodilator and
vasoconstrictor substances. Endothelin-1 (ET-1)1 is one of the
most potent endothelium-derived constricting factors, and
contributes to the regulation of peripheral vascular tone2,3 by
interacting with ETA-4 and ETB-receptors5 on smooth muscle
and endothelial cells.6,7
In several pathological conditions, such as pulmonary8
and systemic essential hypertension,9 heart failure,10,11
atherosclerosis, and obesity,12 ET-1 plasma levels are
elevated and contribute to the increased vascular tone
observed in these disease states. In models of skeletal
muscle deconditioning, such as unilateral limb suspen-
sion13 and bed rest,14 vascular tone is also increased. In the
present study, we hypothesize that the elevated vascular
tone in deconditioned muscles can be explained by an
augmented contribution of ET-1.
Individuals with a spinal cord injury offer a unique
model of nature to assess peripheral vascular adaptations
to inactivity because the skeletal muscles below the level
of the lesion are paralyzed and, therefore, extremely
inactive. Previous research demonstrated that extensive
vascular adaptations, such as an increased leg vascular
tone, occur in the inactive and paralyzed legs of spinal
cord-injured individuals.15 These adaptations cannot be
explained by a reduced availability of nitric oxide16 or
adaptations in the -adrenergic tone.17 According to our
hypothesis, the increased vascular tone in the decondi-
tioned legs of spinal cord-injured individuals is caused by
an augmented contribution of ET-1. To address this
hypothesis we investigated the vasodilator response to
combined ETA- and ETB-receptor blockade in spinal cord-
injured (SCI) individuals as well as in matched controls.
To further explore the causal role of inactivity in alter-
ations in the ET pathway, we repeated the experiments in
SCI individuals after training of the paralyzed legs.
Because a sedentary lifestyle is an independent risk factor
for the development of cardiovascular disease and atheroscle-
rosis,18 insight into the cause and the reversibility of vascular
changes as a result of inactivity is highly relevant.
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Methods
Subjects
Eight SCI individuals (7 men and 1 woman, age: 3812 years; Table
1) and 8 healthy, nonsmoking control subjects (7 men and 1 woman,
age: 3412 years) participated in the study. The SCI individuals
continued their medication throughout the study (Table 1). Two SCI
individuals stopped smoking 2 to 4 weeks before the initial experi-
ment. All SCI individuals except one (incomplete motor lesion from
L3: American Spinal Injury Association19; ASIA C) had complete
motor and sensor spinal cord lesions of traumatic origin varying from
Cervical 5 to Thoracic 12 (ASIA A). The subjects had no history of
cardiovascular disease, were normotensive, had no hypercholester-
olemia, and used no medication known to interfere with the cardio-
vascular system. The study was approved by the hospital ethics
committee. All subjects gave their written informed consent
before participation.
Experimental Design
Control subjects and SCI individuals were studied to quantify the
vasodilator response to blockade of ET-receptors in the leg. Subse-
quently, at least two weeks thereafter, SCI individuals started with a
6 weeks functional electro-stimulated training of the paralyzed legs
to assess whether the observed alterations were reversible on
training. Exactly the same experimental protocol was repeated after
the final training session. In SCI individuals, the role of the ETA- and
ETB-receptor was further explored with selective blockade of the
ETA-receptors.
Protocol
Experiments for both control subjects and SCI individuals started at
8:30 AM after a 12-hour overnight fast. Subjects refrained from
caffeine-containing food and beverages, alcohol, and vitamin C for at
least 18 hours and did not perform any strenuous activities for at least
48 hours before testing. In the last hour and a half before the test,
subjects emptied their bladder to minimize the influence of any
reflex sympathetic activation on peripheral vascular tone. The tests
were performed in a quiet temperature-controlled room
(23.30.6°C), with the subjects in the supine position.
A modified Seldinger technique was used to introduce an intraar-
terial cannula (Angiocath 16 gauge, Becton Dickinson) into the right
femoral artery at the level of the inguinal ligament under local
anesthesia (0.4 mL lidocaine 20 mg/mL). This cannula was used for
the intra-arterial administration of ET-receptor antagonists by an
automatic syringe infusion pump (Type P4000, Welmed Ltd)16,17
and for blood pressure measurement (Type PX600, Edwards Life-
sciences Services GmbH). Heart rate was recorded from the ECG.
After complete instrumentation and at least 30 minutes after cannu-
lation of the femoral artery, an arterial blood sample was taken from
the right femoral artery using a nonheparinized container to deter-
mine baseline plasma ET-1 levels using a chemo-luminescent
immunoassay (QuantiGlo, R&D Systems; sensitivity for ET-10.16
pg/mL). Subsequently, a 30-minute measurement of baseline leg
blood flow during saline infusion into the femoral artery was
performed. Bilateral leg blood flow was measured 3 to 4 times per
minute, using ECG-triggered venous occlusion plethysmography.
For this purpose, an occlusion cuff (12-cm) was placed proximally
around the upper leg and was connected to a rapid cuff inflator
(Hokanson Inc), which inflated the cuff to a pressure of 50 mm Hg
for 9 heart cycles, with 10 heart cycles between the occlusions.20 A
mercury-in-silastic strain gauge (Hokanson Inc) was placed at
mid-thigh, at least 10 cm above the patella and at least 4 cm below
the cuff.21 The lower legs were supported 10 cm above heart level
to facilitate venous outflow between the venous occlusion periods.
After the baseline measurements, the combined infusion of a
selective ETA- and ETB-receptor antagonist (BQ-123 and BQ-788,
respectively, Clinalfa, Calbiochem-Novabiochem AG) was started to
block the ET-receptors of the right leg. BQ-123 and BQ-788 were
infused at 10 and 1 nmol/min/L leg volume, respectively, and the
infusion was continued for 75 minutes.2,22 Total leg-volume was
determined by anthropometry as described and validated by Jones et
al.23 Previous studies showed that a 60-minute coinfusion of BQ-123
and BQ-788 (at, respectively, 10 and 1 nmol/min/L tissue into the
brachial artery) resulted in maximal vasodilation in the forearm of
healthy subjects without triggering any systemic blood pressure
effects.22,24
Selective ETA-Receptor Blockade
To determine the contribution of the ETA-receptor in the observed
effect of dual ETA/B-receptor blockade in SCI individuals, we infused
the selective ETA-receptor antagonist BQ-123 (10 nmol/min/L leg
volume), while the syringe with BQ-788 was replaced by saline.
These experiments were performed at least 21 months after cessation
of the FES-cycling, which is sufficient to exclude any possible
chronic training effect.25 The combined ETA/B-blockade was com-
pared with the selective ETA-receptor blockade to explore the role of
the ETA-receptor in the observed effects in SCI individuals.
Drugs and Solutions
BQ-123 (10 nmol/min/L leg volume) and BQ-788 (1 nmol/min/L leg
volume) were dissolved in saline at the beginning of the experiment.
During the whole protocol, infusion rate was kept constant at 0.1
mL/min/L tissue.
Hybrid Exercise-Training
A stationary computer-controlled functional electro-stimulation
(FES)-ergometer (BerkelBike BV) was used for hybrid FES-cycling
exercise; including stimulated leg-cycling and voluntary arm-
cranking. The FES-ergometer provides stimulation via surface elec-
trodes (58 cm, Farmadomo) to the hamstring, gluteal, and quadri-
ceps muscles. Details regarding this training are described
TABLE 1. Characteristics of Spinal Cord-Injured Individuals
Sex Age (yrs) LL TSI (yrs) Medication
1 M 44 T5 25
2 M 52 T7 20 metanamine, furadantine
3 F 36 T12 3 cibutine, antibiotic, sodium-lauryl-sulfoacetate and
sodium-citrate-sorbitol (microlax)
M 46 T8 10
5 M 43 C5 24 bisacodyl, baclofen
6 M 25 T4 2 methylphenadate (Ritalin), imipramine
7 M 38 C7 13 dantrium, baclofen, oxybutinine
8 M 24 T6 4
Average: 383 133
LL indicates level of lesion, TSI; time since injury
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elsewhere.26 SCI individuals trained twice a week for 6 weeks.
Compliance with the training sessions was 100%.
Data Analysis
Plethysmographic data of both legs were digitalized with a sample
frequency of 100 Hz (MIDAC, Instrumentation Department, Rad-
boud University Nijmegen Medical Centre) and analyzed off-line by
a customized computer program (Matlab, Mathworks Inc). Leg
blood flow (in ml/min per dl of leg tissue) was calculated as the slope
of the volume change curve over a 4-second interval, starting directly
after the inflation-induced cuff artifact (2 seconds).21 Thigh vascular
resistance was calculated as the mean arterial pressure (mm Hg)
divided by thigh blood flow (in ml/min/dL) and expressed in
arbitrary units (AU; mm Hg/mL/min/dL).
Because of the differences in baseline vascular characteristics
between SCI and control subjects, analysis of absolute values could
affect the comparison between both groups. Therefore, data were
expressed as percentage changes from baseline. Baseline blood flow
and vascular resistance were calculated by averaging registrations
over a 10-minute interval before the infusion of the ET-receptor
blockers. In addition, leg blood flow was expressed as the ratio
between the infused and control (contra-lateral) leg to correct for
possible random systemic changes.27 An increase of the flow ratio
during ET-receptor blockade indicates vasodilation in the leg vascu-
lar bed, suggesting a relevant role for endogenous ET-1 in the
regulation of baseline vascular tone. Blood flow, vascular resistance,
and blood flow ratio were analyzed over the last 10 minutes, where
ET-receptor blockade reached its maximal effect (Figure 1)28,29
Statistics
The primary end point of this study is the vasodilator response to
ET-receptor blockade in the leg. We decided that with an estimated
SD of 20% of the baseline value, a mean relevant effect of the
ET-receptor blockade should be at least 25% (for the control versus
SCI comparison) or 17.5% (for the before versus after training
comparison) and calculated that with an alpha of 0.05, 8 subjects per
group would be needed to achieve a power of 80%. Kolmogorov-
Smirnov test indicated a normal (Gaussian) distribution of data.
Results are expressed as meanSE. To assess differences between
SCI individuals and controls (unpaired) and between the pre– and
post–FES-training measurement (paired), the maximal effect of
ET-receptor blockade (as defined as the average of the final 10
minutes of infusion) was compared using a Student t test. Differ-
ences were considered to be statistically significant at a 2-sided
probability value of 0.05.
Results
Baseline Characteristics
Because of muscle spasms in one SCI subject and of technical
problems in one control subject, the data of the noninfused leg
were not available for analysis in these 2 subjects. Baseline leg
blood flow was significantly lower in SCI individuals as com-
pared with controls (Table 2; t test: P0.05). The training
procedure increased baseline leg blood flow in SCI individuals
(Table 2). Leg volume of SCI individuals was lower as com-
pared with control subjects, but increased in response to the
training procedure (Table 2). Baseline mean arterial pressure,
heart rate, and plasma ET-1 levels were not different between
SCI individuals and controls, and did not change by training in
SCI individuals (Table 2).
Dual ET-Receptor Blockade in Controls and
SCI Individuals
Controls
Blockade of the ET-receptors did not affect mean arterial
pressure, heart rate, or blood flow and vascular resistance in
the noninfused leg in the control subjects (Table 2). The
ET-receptor blockade induced a small but significant change
in blood flow (104%) and vascular resistance (104%)
of the infused leg. As such, the blood flow ratio between both
legs increased by 94% (Figures 1 and 2).
SCI Individuals
During the ET-receptor blockade in SCI individuals, heart
rate did not change, whereas mean arterial pressure signifi-
cantly decreased (Table 2). After ET-receptor blockade,
blood flow clearly increased in the infused leg of the SCI
individuals (415%, Figure 2). In the noninfused leg, a slight
but significant increase in blood flow was observed (176%,
Table 2). Blockade of the ET-receptors induced a significant
increase in the blood flow ratio (225%, Figures 1 and 2).
Controls Versus SCI Individuals
In contrast to controls, blockade of the ET-receptors induced
a significant decrease in mean arterial pressure in the SCI
individuals (Table 2). The change in blood flow and vascular
resistance of the infused leg during ET-receptor blockade in
SCI was larger than in the controls. Likewise, the increase in
blood flow ratio in response to the ET-receptor blockade was
significantly larger in SCI individuals (Figures 1 and 2).
Dual ET-Receptor Blockade in SCI Individuals
After FES-Cycling
SCI Individuals After FES-Cycling
ET-receptor blockade did not change heart rate but decreased
mean arterial pressure. After training, blood flow of the
infused and noninfused leg both increased during the infusion
protocol (293 and 246%, respectively, Table 2). Vascular
resistance of both legs decreased during ET-receptor block-
ade (312 and295%, respectively, Table 2). The blood
flow ratio did not change during blockade of the ET-receptors
(Figures 1 and 2).
Figure 1. Percentage increase in blood flow ratio during the
ET-receptor blockade in controls (C, F, n8) and spinal cord-
injured individuals (n8), both before (SCI, f) and after the
training procedure (SCI-training, ). Each symbol represents the
change in blood flow ratio over 15 minutes, with the error bars
representing the SE. The black square indicates the maximal
effect during the final 10 minutes of the ET-receptor blockade.
This effect was used for statistical analysis (see Figure 2)
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Pre-Training Versus Post-Training
The response of heart rate and mean arterial pressure to
ET-receptor blockade did not differ between pre- and post-
training measurements. The increase in leg blood flow in the
infused leg as well as the flow ratio during ET-receptor
blockade were significantly lower after training than before
(Figure 2), whereas the difference between the pre- and
post-training fall in vascular resistance did not reach statisti-
cal significance (Table 2).
Selective ETA-Receptor Blockade
Because of medical problems (n2) and withdrawal (n2),
we examined a subset of the SCI individuals (n4, male,
3612 years). At least 21 months after cessation of the
exercise training, baseline characteristics did not differ be-
tween both situations (Table 3). During selective ETA-
receptor blockade in SCI individuals, heart rate did not
change. Mean arterial pressure showed a decrease, but did not
reach statistical significance (Table 3). After ETA-receptor
blockade, blood flow increased in the infused leg (Figure 3),
but did not change significantly in the noninfused leg (Table
3). Blockade of the ETA-receptor induced an increase in the
blood flow ratio, but did not reach statistical significance
(Figure 3). The hemodynamic responses did not differ be-
tween selective ETA- and combined ETA/B-receptor blockade
(Table 3, Figure 3).
Discussion
The present study provides three interesting and clinically
important new findings: (1) endogenous ET-1 hardly contributes
to baseline vascular tone in the leg of healthy control subjects;
(2) in contrast, in SCI individuals endogenous ET-1 has a
prominent role in the regulation of vascular tone in the decon-
ditioned leg; and (3) exercise training in SCI individuals reverses
the ET-1-pathway, which normalizes basal leg vascular tone.
Based on the fact that ET-1 plasma levels did not change, our
findings in SCI may be explained by an upregulation of the
ET-receptor sensitivity or signaling. Thus, our results indicate
that intensive long-term inactivity in humans results in a signif-
icant, though reversible, ET-1–mediated vasoconstrictor state in
the skeletal muscle vascular bed.
In contrast to previous studies, using the perfused forearm
model, we only observed a slight vasodilator effect of ET-1
blockade (9% increase in blood flow) in the leg of healthy
subjects, whereas forearm blood flow increased by 35% to
TABLE 2. Dual ETA/B-Receptor Blockade in Controls (n8) and SCI (n8) Before and After Training
Controls (n8) SCI Pre-Training (n8) SCI Post-Training (n8)
Baseline End-Infusion P Baseline End-Infusion P Baseline End-Infusion P
Leg volume, l 9.30.3 7.50.5* 7.90.5†
ET-1, pg/ml1 0.910.20 0.550.09 0.610.14
HR, bpm 574 594 0.10 572 593 0.30 572 583 0.54
MAP, mm Hg 843 844 0.77 933 844* 0.006 904 814 0.01
Infused leg
BF, ml/min/dl 3.60.4 3.90.5 0.06 2.40.4* 3.40.5 0.0001 3.20.5† 4.10.7 0.0004
BF, % 1000 1104 0.03 1000 1415* 0.0001 1000 1293† 0.0001
VR, AU 274 244 0.01 446* 295 0.0001 334† 234 0.0001
VR, % 1000 904 0.02 1000 652* 0.0001 1000 692 0.0001
Non-infused leg
BF, ml/min/dl 3.50.4 3.70.5 0.22 2.10.2* 2.50.3 0.02 2.30.3 2.80.4 0.005
BF, % 1000 1044 0.34 1000 1176 0.02 1000 1246 0.003
VR, AU 283 274 0.38 464* 386 0.01 444 335 0.002
VR, % 1000 954 0.18 1000 815* 0.01 1000 715 0.001
Infused and non-infused leg
Flow ratio, % 1000 1094 0.04 1000 1225* 0.002 1000 1054† 0.24
Vascular characteristics are presented for controls (n8) and spinal cord-injured (SCI) individuals (n8) before the start of the infusion (Baseline)
and at the end of the infusion of ET-receptor antagonists (last 10 minutes, End-infusion). The columns with P-values refer to a paired t test between
Baseline and End-infusion. Data are presented as meanSE.
*P0.05 from controls (t test); †P0.05 from SCI pre-training (t test)
Figure 2. The mean (SE) percentage increase in blood flow
ratio or blood flow, induced by the ET-receptor blockade in
controls (C, n8) and spinal cord-injured individuals (n8), both
before (SCI) and after the training procedure (SCI-training). *Sig-
nificant relative increase from baseline.
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60% during infusion of the ET-receptor antagonists BQ-123
and BQ-788.2,3,28 The difference in response to ET-receptor
blockade between forearm and leg vascular bed suggests that
ET-1 has a different physiological effect on the lower limbs
than on the upper limbs in healthy subjects. Recently,
Newcomer et al30 reported significantly different responses
for human forearm and leg vascular beds to endothelium-
dependent (acetylcholine and substance P) and -independent
(sodium nitroprusside) stimuli. Moreover, infusion of ET-1 in
the rat hindquarters skeletal muscle bed results in a signifi-
cantly lower vasoconstrictor response as compared with the
mesenteric bed.31 It may be hypothesized that the level of
activity may partly explain the differences in contribution of
ET-1 to vascular tone between both limbs. The average level
of skeletal muscle activity varies markedly between the upper
and lower extremities. As bipeds, the legs are far more active
during daily life (ie, locomotion, standing) and during sports
activities (ie, running, cycling) than the human forearm.
The larger vasodilator response to ET-receptor blockade in
SCI individuals compared with controls indicates that ET-1
importantly contributes to the elevated baseline leg vascular
tone in SCI. Moreover, because ET-receptor blockade elim-
inates the difference in leg blood flow between SCI and
control subjects, ET-1 may even be primarily responsible for
the increased basal leg vascular tone in SCI. This agrees with
previous studies from our department which excluded a role
for nitric oxide16 or for -adrenergic receptor-mediated ef-
fects17 in the elevated leg vascular tone in SCI individuals.
Apart from the sympathetic denervation, the main difference
between SCI individuals and controls is the paralysis of the
legs, resulting in an extreme inactivity of the legs. This
suggests a functional link between the contribution of ET-1 to
vascular tone and inactivity, which is supported by the second
part of our study demonstrating that exercise training in SCI
individuals attenuates the contribution of ET-1 to leg vascular
tone. This observation is in line with recent animal studies
that report exercise training in healthy animals to result in a
downregulation of the ET pathway. For example, a decrease
in receptor sensitivity to ET-1 in pig coronary arteries32 and
rat aortic and cerebellar vessels33 is reported after exercise
training. However, the reversal of the contribution of ET-1 to
leg vascular tone in our study was not complete, suggesting
that ET-1 may not be the only factor in vascular adaptation to
SCI or, alternatively, that the training period did not last long
enough.
The mechanism behind the adaptation of the ET pathway
to (in)activity remains to be solved. In the present study, ET-1
plasma levels were not different before and after training in
SCI individuals, nor between controls and SCI individuals.
This indicates that different ET-1 plasma levels cannot
explain the changes in the contribution of ET-1 to leg
vascular tone with (in)activity. As such, changes in sensitivity
(and/or density) of the ETA- and ETB-receptors or changes in
endothelin receptor signaling are more likely to explain the
inactivity-induced upregulation of the ET pathway. The
magnitude of the response to selective ETA-receptor blockade
in the subset of SCI individuals is similar to the vascular
response observed during dual blockade of the ETA/B-
receptors. In combination with the marked increase in blood
flow during ET-blockade in the SCI subjects, these results
indicate that the ETA-receptor mediates the increased contri-
bution of ET-1 to leg vascular tone in SCI subjects. A strong
argument against a role of the ETB-receptor is related to the
fact that these receptors mediate vasodilation by endothelial
generation of nitric oxide (NO).2 We recently demonstrated
that the contribution of NO to baseline leg vascular tone is
preserved in SCI subjects as examined with infusion of
L-NMMA in the femoral artery.16 Because the vasodilator
properties induced by agonism of the ETB-receptors are
mediated by NO, the ETB-receptor cannot account for the
increased ET-1-mediated vasoconstriction observed in the
legs of SCI subjects.
Figure 3. The mean (SE) percentage increase in blood flow
ratio or blood flow (BF) in the infused leg in spinal cord-injured
individuals (n4) during infusion of the combined ETA/B- (black
bars) and selective ETA-receptor antagonists (open bars). Error
bars represent SE.
TABLE 3. Dual and Selective ETA-Receptor Blockade in
SCI (n4)
Dual ET-Receptor Blockade Selective ETA-Receptor Blockade
Baseline End-Infusion Baseline End-Infusion
HR, bpm 583 594 576 627
MAP, mmHg 902 813* 892 833
Infused leg
BF, ml/min/dl 2.30.3 3.30.5* 3.10.5 4.60.3*
BF, % 1000 1437* 1000 15318*
VR, AU 427 275* 304 181*
VR, % 1000 643* 1000 637*
Non-infused leg
BF, ml/min/dl 2.00.2 2.40.3 3.41.0 4.00.8
BF, % 1000 1198 1000 13518
VR, AU 465 367* 3510 234
VR, % 1000 768* 1000 7310
Infused and non-infused leg
Flow ratio, % 1000 1178 1000 1178
Vascular characteristics are presented for a subset of spinal cord-injured
(SCI) individuals (n4), before the start of the infusion (Baseline) and at the end
of the infusion of the dual ETA/B- and selective ETA-receptor antagonists (last 10
minutes, End-infusion). Data are presented as meanSE.
* P0.05 from Baseline (t test)
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Because both groups were sex-matched, each population
consisted of 7 males and 1 female. Interestingly, there was no
gender difference noted in any of the measured parameters.
Excluding the female subjects did not change the magnitude
of the data outcome measures.
Clinical Relevance
SCI individuals are prone to develop decubitus and have poor
wound healing, which may be caused by the increased leg
vascular tone. Based on the constrictor action of ET-1 in SCI,
pharmacological interventions that block the ET-1 activity
may improve or prevent these pathologic conditions. Pro-
longed administration may even improve general cardiovas-
cular function, but at present, no data are available. Increasing
evidence supports a pathophysiological role for ET-1 in the
modulation of vascular tone in cardiovascular disease.8,34
Based on our findings one should realize that the increased
contribution of ET-1 in basal vascular tone in cardiovascular
disease result from the reduced level of inactivity. Therefore,
inactivity, rather than the pathology of these specific cardio-
vascular diseases, is emerging as a strong candidate to explain
the ET-1-mediated elevated vascular tone in cardiovascular
disease.
Limitations
In this study we used local infusions of drugs into the femoral
artery. Because the leg represents an 8-fold larger vascular
bed as compared with the forearm, higher dosages were
necessary, and therefore systemic spill-over effects may have
occurred. Control subjects, however, showed no change in
mean arterial pressure or heart rate during ET-receptor
blockade. In SCI individuals, although the same protocol was
used, a significant decrease in mean arterial pressure was
found. This change in arterial pressure is most likely medi-
ated through the ET-receptor blockade-induced vasodilation,
without the concomitant contra-regulation via baroreflex-
mediated sympathetic vasoconstriction in SCI. The nonin-
fused leg showed a vasodilator response, indicating a sys-
temic vascular effect, which may be caused by a minor
spillover of the ET-antagonists. Differences in body compo-
sition between controls and SCI individuals (eg, less fat-free
mass in SCI35) may have contributed to the spillover. As a
consequence of the vasodilation in the control limb in SCI,
flow ratios underestimate unilateral vascular changes in the
infused leg.36 The contribution of ET-1 to leg vascular tone in
SCI may, therefore, be even more pronounced than indicated
by the flow ratio. Although in this study design it was not
possible to avoid systemic actions of the ET-receptor antag-
onists, these issues will not alter the major outcome of the
study.
In conclusion, compared with the minor effect of ET-1 on
leg vascular tone in healthy subjects, ET-1 is a key mediator
in the increased leg vascular tone in SCI individuals. In
addition, data of this study indicate that exercise training can
reverse the contribution of ET-1 to vascular tone in SCI.
These adaptations in the ET pathway may be the result of
changes in ETA-receptor sensitivity or signaling, rather than
changes in plasma levels of ET-1. Thus, inactivity appears to
upregulate the ET pathway in the human skeletal muscle
vascular bed.
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